Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

It was a bold choice to host a preview screening of The Thinking Game, a documentary about AI company Google DeepMind and its ...

Google DeepMind CEO Demis Hassabis's AI journey had an unexpected start: his early mastery of chess. Years before Hassabis ...

Google’s DeepMind is reportedly holding back from publishing AI research papers over fears of losing its competitive edge.

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

Google’s artificial intelligence arm DeepMind has been holding back the release of its world-renowned research, as it seeks ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

FREE TO READ] Google’s AI arm led by Demis Hassabis makes it harder for its researchers to publish studies in major change in approach ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...